Annual report pursuant to Section 13 and 15(d)

Cover Page

Cover Page - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Feb. 24, 2021
Cover [Abstract]    
Document Type 10-K  
Document Annual Report true  
Current Fiscal Year End Date --12-31  
Document Period End Date Dec. 31, 2020  
Document Transition Report false  
Entity File Number 001-36421  
Entity Registrant Name Aurinia Pharmaceuticals Inc.  
Entity Incorporation, State or Country Code Z4  
Entity Tax Identification Number 46-4129078  
Entity Address, Address Line One #1203-4464 Markham Street  
Entity Address, City or Town Victoria  
Entity Address, State or Province BC  
Entity Address, Postal Zip Code V8Z 7X8  
City Area Code (250)  
Local Phone Number 708-4272  
Title of 12(b) Security Common shares, no par value  
Trading Symbol AUPH  
Security Exchange Name NASDAQ  
Entity Well-known Seasoned Issuer Yes  
Entity Voluntary Filers No  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
ICFR Auditor Attestation Flag true  
Entity Shell Company false  
Entity Public Float $ 1,740  
Entity Common Stock, Shares Outstanding   127,450,815
Documents Incorporated by Reference Portions of the registrant’s definitive proxy statement to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A within 120 days after registrant’s fiscal year end of December 31, 2020 are incorporated by reference into Part III of this Annual Report on Form 10-K.  
Amendment Flag false  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus FY  
Entity Central Index Key 0001600620